Federal genomic research program opens door to private biotech profit
S. 4991 — Homestake AI Act of 2026 · Filed by Mike Rounds (R-SD) · 1 cosponsor · Introduced Jul 15, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill establishes a federal initiative to collect, sequence, and store the complete genomes of extremophile organisms (animals, plants, fungi, and microbes found in extreme environments like deep mines) to advance scientific discovery and develop new medical treatments for cancer, diabetes, and dementia. The Department of Energy will select at least 5 collection sites, build a long-term underground storage facility, create a public database of genomic data (restricted from adversary nations), and coordinate with universities, private biotech companies, and allied nations to share research.
Why we flagged it
The bill's core function is establishing a federally funded genomic research program and database. While it includes private-sector coordination and a foundation to receive in-kind contributions from biotech companies, the primary mechanism is public research infrastructure, not corporate subsidy or deregulation.
What the text implies
- The bill creates a public genomic database accessible to U.S. researchers but restricts access from 'adversary nations'—a national-security framing that may expand over time and could limit international scientific collaboration.
- Private biotech and AI companies gain access to federally funded genomic data and samples without explicit IP restrictions or benefit-sharing requirements, potentially allowing private profit from public research.
The full analysis lists 4 implications of this text.
Who stands to gain
biotechnology companies; pharmaceutical companies; artificial intelligence companies